BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chun P. Histone deacetylase inhibitors in hematological malignancies and solid tumors. Arch Pharm Res 2015;38:933-49. [PMID: 25653088 DOI: 10.1007/s12272-015-0571-1] [Cited by in Crossref: 77] [Cited by in F6Publishing: 65] [Article Influence: 9.6] [Reference Citation Analysis]
Number Citing Articles
1 Rossi M, De Martino V, Di Giuseppe L, Battafarano G, Di Gregorio J, Terreri S, Marampon F, Minisola S, Del Fattore A. Anti-proliferative, pro-apototic and anti-migratory properties of HDAC inhibitor PXD-101 on osteosarcoma cell lines. Arch Biochem Biophys 2023;734:109489. [PMID: 36526001 DOI: 10.1016/j.abb.2022.109489] [Reference Citation Analysis]
2 Pramanik SD, Kumar Halder A, Mukherjee U, Kumar D, Dey YN, R M. Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer. Front Chem 2022;10:948217. [DOI: 10.3389/fchem.2022.948217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Alseksek RK, Ramadan WS, Saleh E, El-awady R. The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention. IJMS 2022;23:8141. [DOI: 10.3390/ijms23158141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Pandey M, Lalwani A, Mehta R. Epigenetics of Breast Cancer. Breast Cancer: Current Trends in Molecular Research 2022. [DOI: 10.2174/9781681089522112010010] [Reference Citation Analysis]
5 Sengupta P, Choudhury H, Dutta S, Jacob S, Kesharwani P, Gorain B. Current Strategies in Breast Cancer Therapy: Role of Epigenetics and Nanomedicine. Part & Part Syst Charact. [DOI: 10.1002/ppsc.202100276] [Reference Citation Analysis]
6 Ruzic D, Djoković N, Srdić-rajić T, Echeverria C, Nikolic K, Santibanez JF. Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention. Pharmaceutics 2022;14:209. [DOI: 10.3390/pharmaceutics14010209] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
7 Rubio C, Avendaño-Ortiz J, Ruiz-Palomares R, Karaivanova V, Alberquilla O, Sánchez-Domínguez R, Casalvilla-Dueñas JC, Montalbán-Hernández K, Lodewijk I, Rodríguez-Izquierdo M, Munera-Maravilla E, Nunes SP, Suárez-Cabrera C, Pérez-Crespo M, Martínez VG, Morales L, Pérez-Escavy M, Alonso-Sánchez M, Lozano-Rodríguez R, Cueto FJ, Aguirre LA, Guerrero-Ramos F, Paramio JM, López-Collazo E, Dueñas M. Toward Tumor Fight and Tumor Microenvironment Remodeling: PBA Induces Cell Cycle Arrest and Reduces Tumor Hybrid Cells' Pluripotency in Bladder Cancer. Cancers (Basel) 2022;14:287. [PMID: 35053451 DOI: 10.3390/cancers14020287] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Quaas CE, Long DT. Targeting (de)acetylation: A Diversity of Mechanism and Disease. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00076-1] [Reference Citation Analysis]
9 Dallavalle S, Musso L, Cincinelli R, Darwiche N, Gervasoni S, Vistoli G, Guglielmi MB, La Porta I, Pizzulo M, Modica E, Prosperi F, Signorino G, Colelli F, Cardile F, Fucci A, D'Andrea EL, Riccio A, Pisano C. Antitumor activity of novel POLA1-HDAC11 dual inhibitors. Eur J Med Chem 2021;:113971. [PMID: 34772529 DOI: 10.1016/j.ejmech.2021.113971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Bauer I, Graessle S. Fungal Lysine Deacetylases in Virulence, Resistance, and Production of Small Bioactive Compounds. Genes (Basel) 2021;12:1470. [PMID: 34680865 DOI: 10.3390/genes12101470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Mehrpouri M, Pourbagheri-Sigaroodi A, Bashash D. The contributory roles of histone deacetylases (HDACs) in hematopoiesis regulation and possibilities for pharmacologic interventions in hematologic malignancies. Int Immunopharmacol 2021;100:108114. [PMID: 34492531 DOI: 10.1016/j.intimp.2021.108114] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Gameiro A, Urbano AC, Ferreira F. Emerging Biomarkers and Targeted Therapies in Feline Mammary Carcinoma. Vet Sci 2021;8:164. [PMID: 34437486 DOI: 10.3390/vetsci8080164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Karagiannis D, Rampias T. HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity. Cancers (Basel) 2021;13:3575. [PMID: 34298787 DOI: 10.3390/cancers13143575] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
14 Peng X, Chen J, Li L, Sun Z, Liu J, Ren Y, Huang J, Chen J. Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents. J Med Chem 2021;64:8447-73. [PMID: 34097389 DOI: 10.1021/acs.jmedchem.1c00413] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
15 Cortes JR, Patrone CC, Quinn SA, Gu Y, Sanchez-Martin M, Mackey A, Cooke AJ, Shih BB, Laurent AP, Trager MH, Ferrando AA, Geskin LJ, Palomero T. Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma. J Invest Dermatol 2021:S0022-202X(21)01308-7. [PMID: 34089720 DOI: 10.1016/j.jid.2021.04.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
16 Pavlidis A, Piperi C, Papadavid E. Novel therapeutic approaches for cutaneous T cell lymphomas. Expert Rev Clin Immunol 2021;17:629-41. [PMID: 33890833 DOI: 10.1080/1744666X.2021.1919085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Pasyukova EG, Symonenko AV, Rybina OY, Vaiserman AM. Epigenetic enzymes: A role in aging and prospects for pharmacological targeting. Ageing Res Rev 2021;67:101312. [PMID: 33657446 DOI: 10.1016/j.arr.2021.101312] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
18 Das TK, Gatto J, Mirmira R, Hourizadeh E, Kaufman D, Gelb BD, Cagan R. Drosophila RASopathy models identify disease subtype differences and biomarkers of drug efficacy. iScience 2021;24:102306. [PMID: 33855281 DOI: 10.1016/j.isci.2021.102306] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
19 Almeida F, Gameiro A, Correia J, Ferreira F. Histone Deacetylase Inhibitors and Microtubule Inhibitors Induce Apoptosis in Feline Luminal Mammary Carcinoma Cells. Animals (Basel) 2021;11:502. [PMID: 33671894 DOI: 10.3390/ani11020502] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
20 Chun P. Histone deacetylase inhibitors in medical therapeutics. Medical Epigenetics 2021. [DOI: 10.1016/b978-0-12-823928-5.00029-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Stadler R, Scarisbrick JJ. Maintenance therapy in patients with mycosis fungoides or Sézary syndrome: A neglected topic. Eur J Cancer 2021;142:38-47. [PMID: 33217680 DOI: 10.1016/j.ejca.2020.10.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
22 Watters JM, Wright G, Smith MA, Shah B, Wright KL. Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function. Biochem Biophys Res Commun 2021;534:773-9. [PMID: 33190829 DOI: 10.1016/j.bbrc.2020.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
23 Das TK, Gatto J, Mirmira R, Hourizadeh E, Kaufman D, Gelb BD, Cagan R. Drosophila RASopathy Models Identify Disease Subtype Differences and Biomarkers of Drug Efficacy.. [DOI: 10.1101/2020.10.30.362350] [Reference Citation Analysis]
24 Friedrich A, Assmann AS, Schumacher L, Stuijvenberg JV, Kassack MU, Schulz WA, Roos WP, Hansen FK, Pflieger M, Kurz T, Fritz G. In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi). Int J Mol Sci 2020;21:E4747. [PMID: 32635356 DOI: 10.3390/ijms21134747] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Xu L, Jiao J, Sun X, Sang W, Gao X, Yang P, Yan D, Song X, Sun C, Liu M, Qin Y, Tian Y, Zhu F, Zeng L, Li Z, Xu K. Cladribine Induces ATF4 Mediated Apoptosis and Synergizes with SAHA in Diffuse Large B-Cell Lymphoma Cells. Int J Med Sci 2020;17:1375-84. [PMID: 32624694 DOI: 10.7150/ijms.41793] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
26 Karai E, Szebényi K, Windt T, Fehér S, Szendi E, Dékay V, Vajdovich P, Szakács G, Füredi A. Celecoxib Prevents Doxorubicin-Induced Multidrug Resistance in Canine and Mouse Lymphoma Cell Lines. Cancers (Basel) 2020;12:E1117. [PMID: 32365663 DOI: 10.3390/cancers12051117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
27 Yue L, Sharma V, Horvat NP, Akuffo AA, Beatty MS, Murdun C, Colin C, Billington JMR, Goodheart WE, Sahakian E, Zhang L, Powers JJ, Amin NE, Lambert-Showers QT, Darville LN, Pinilla-Ibarz J, Reuther GW, Wright KL, Conti C, Lee JY, Zheng X, Ng PY, Martin MW, Marshall CG, Koomen JM, Levine RL, Verma A, Grimes HL, Sotomayor EM, Shao Z, Epling-Burnette PK. HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms. Blood 2020;135:191-207. [PMID: 31750881 DOI: 10.1182/blood.2019895326] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
28 Nepali K, Chang TY, Lai MJ, Hsu KC, Yen Y, Lin TE, Lee SB, Liou JP. Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors. Eur J Med Chem 2020;196:112291. [PMID: 32325365 DOI: 10.1016/j.ejmech.2020.112291] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
29 Myasoedova VA, Sukhorukov V, Grechko AV, Zhang D, Romanenko E, Orekhov V, Orekhov AN. Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy. Curr Pharm Des 2019;25:635-41. [PMID: 30950345 DOI: 10.2174/1381612825666190405144026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
30 Igaz N, Szőke K, Kovács D, Buhala A, Varga Z, Bélteky P, Rázga Z, Tiszlavicz L, Vizler C, Hideghéty K, Kónya Z, Kiricsi M. Synergistic Radiosensitization by Gold Nanoparticles and the Histone Deacetylase Inhibitor SAHA in 2D and 3D Cancer Cell Cultures. Nanomaterials 2020;10:158. [DOI: 10.3390/nano10010158] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
31 Ganai SA. Conspectus of Structurally Distinct Groups of Histone Deacetylase Inhibitors of Classical Histone Deacetylases and Sirtuins. Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy 2020. [DOI: 10.1007/978-981-15-8179-3_8] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Gameiro A, Almeida F, Soares M, Correia J, Ferreira F. Feline Mammary Carcinoma: Past, Present and Future. Advances in Animal Health, Medicine and Production 2020. [DOI: 10.1007/978-3-030-61981-7_23] [Reference Citation Analysis]
33 Zhang S, Gong C, Su M, Chen F, He T, Zhang Y, Shen Q, Su Y, Ding J, Li J, Chen Y, Nan F. Synthesis and in Vitro and in Vivo Biological Evaluation of Tissue-Specific Bisthiazole Histone Deacetylase (HDAC) Inhibitors. J Med Chem 2020;63:804-15. [DOI: 10.1021/acs.jmedchem.9b01792] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
34 Soumyanarayanan U, Ramanujulu PM, Mustafa N, Haider S, Fang Nee AH, Tong JX, Tan KS, Chng WJ, Dymock BW. Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor. European Journal of Medicinal Chemistry 2019;184:111755. [DOI: 10.1016/j.ejmech.2019.111755] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
35 Chowdury MA, Heileman KL, Moore TA, Young EWK. Biomicrofluidic Systems for Hematologic Cancer Research and Clinical Applications. SLAS Technol 2019;24:457-76. [PMID: 31173533 DOI: 10.1177/2472630319846878] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
36 Oka T, Miyagaki T. Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome. Front Med (Lausanne) 2019;6:116. [PMID: 31192214 DOI: 10.3389/fmed.2019.00116] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
37 Gervasini G. Pharmacogenetics and personalized medicine. Are expectations being met? Med Clin (Barc) 2019;152:368-71. [PMID: 30611536 DOI: 10.1016/j.medcli.2018.12.001] [Reference Citation Analysis]
38 Gervasini G. Pharmacogenetics and personalized medicine. Are expectations being met? Medicina Clínica (English Edition) 2019;152:368-371. [DOI: 10.1016/j.medcle.2018.12.013] [Reference Citation Analysis]
39 Pasyukova EG, Symonenko AV, Rybina OY. Epigenetic Drugs. Reference Module in Biomedical Sciences 2019. [DOI: 10.1016/b978-0-12-801238-3.11298-x] [Reference Citation Analysis]
40 Safa AR. Cancer Stem Cells, Apoptosis Pathways and Mechanisms of Death Resistance. Oncogenomics 2019. [DOI: 10.1016/b978-0-12-811785-9.00007-7] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
41 Lopez AT, Bates S, Geskin L. Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma. Am J Clin Dermatol 2018;19:805-19. [PMID: 30173294 DOI: 10.1007/s40257-018-0380-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
42 Ghayad SE, Rammal G, Sarkis O, Basma H, Ghamloush F, Fahs A, Karam M, Harajli M, Rabeh W, Mouawad JE, Zalzali H, Saab R. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma. Cancer Biol Ther 2019;20:272-83. [PMID: 30307360 DOI: 10.1080/15384047.2018.1529093] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
43 Cincinelli R, Musso L, Artali R, Guglielmi MB, La Porta I, Melito C, Colelli F, Cardile F, Signorino G, Fucci A, Frusciante M, Pisano C, Dallavalle S. Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents. PLoS One 2018;13:e0205018. [PMID: 30300374 DOI: 10.1371/journal.pone.0205018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
44 Levinzon L, Madigan M, Nguyen V, Hasic E, Conway M, Cherepanoff S. Tumour Expression of Histone Deacetylases in Uveal Melanoma. Ocul Oncol Pathol 2019;5:153-61. [PMID: 31049320 DOI: 10.1159/000490038] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
45 Geng Y, Liu J, Xie Y, Jiang H, Zuo K, Li T, Liu Z. Trichostatin A promotes GLI1 degradation and P21 expression in multiple myeloma cells. Cancer Manag Res 2018;10:2905-14. [PMID: 30214285 DOI: 10.2147/CMAR.S167330] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
46 Ganai SA, Farooq Z, Banday S, Altaf M. In silico approaches for investigating the binding propensity of apigenin and luteolin against class I HDAC isoforms. Future Med Chem 2018;10:1925-45. [PMID: 29992822 DOI: 10.4155/fmc-2018-0020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
47 Dias JNR, Aguiar SI, Pereira DM, André AS, Gano L, Correia JDG, Carrapiço B, Rütgen B, Malhó R, Peleteiro C, Goncalves J, Rodrigues CMP, Gil S, Tavares L, Aires-da-Silva F. The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma. Oncotarget 2018;9:28586-98. [PMID: 29983882 DOI: 10.18632/oncotarget.25580] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
48 Doroshow DB, Eder JP, LoRusso PM. BET inhibitors: a novel epigenetic approach. Ann Oncol 2017;28:1776-87. [PMID: 28838216 DOI: 10.1093/annonc/mdx157] [Cited by in Crossref: 196] [Cited by in F6Publishing: 201] [Article Influence: 39.2] [Reference Citation Analysis]
49 Fan CW, Yarravarapu N, Shi H, Kulak O, Kim J, Chen C, Lum L. A synthetic combinatorial approach to disabling deviant Hedgehog signaling. Sci Rep 2018;8:1133. [PMID: 29348431 DOI: 10.1038/s41598-018-19408-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
50 Pasculli B, Barbano R, Parrella P. Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine. Semin Cancer Biol 2018;51:22-35. [PMID: 29339244 DOI: 10.1016/j.semcancer.2018.01.007] [Cited by in Crossref: 80] [Cited by in F6Publishing: 71] [Article Influence: 16.0] [Reference Citation Analysis]
51 Chun P. Therapeutic effects of histone deacetylase inhibitors on kidney disease. Arch Pharm Res 2018;41:162-83. [PMID: 29230688 DOI: 10.1007/s12272-017-0998-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
52 Aristizabal Prada ET, Auernhammer CJ. Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets. Endocr Connect 2018;7:R1-R25. [PMID: 29146887 DOI: 10.1530/EC-17-0286] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
53 Pasyukova EG, Vaiserman AM. HDAC inhibitors: A new promising drug class in anti-aging research. Mechanisms of Ageing and Development 2017;166:6-15. [DOI: 10.1016/j.mad.2017.08.008] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 10.7] [Reference Citation Analysis]
54 van den Bosch T, Kwiatkowski M, Bischoff R, Dekker FJ. Targeting transcription factor lysine acetylation in inflammatory airway diseases. Epigenomics 2017;9:1013-28. [PMID: 28617138 DOI: 10.2217/epi-2017-0027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
55 Mazzone R, Zwergel C, Mai A, Valente S. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clin Epigenetics 2017;9:59. [PMID: 28572863 DOI: 10.1186/s13148-017-0358-y] [Cited by in Crossref: 103] [Cited by in F6Publishing: 108] [Article Influence: 17.2] [Reference Citation Analysis]
56 Berndsen RH, Abdul UK, Weiss A, Zoetemelk M, te Winkel MT, Dyson PJ, Griffioen AW, Nowak-sliwinska P. Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment. Angiogenesis 2017;20:245-67. [DOI: 10.1007/s10456-017-9551-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
57 Shieh J, Tang Y, Hu F, Huang W, Wang Y, Jen J, Liao S, Lu Y, Yeh Y, Wang T, Lin P, Wang Y. A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer: Antitumor effects and signals of TMU-35435. Int J Cancer 2017;140:2375-86. [DOI: 10.1002/ijc.30664] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
58 Frère A, Baroni A, Hendrick E, Delvigne A, Orange F, Peulen O, Dakwar GR, Diricq J, Dubois P, Evrard B, Remaut K, Braeckmans K, De Smedt SC, Laloy J, Dogné J, Feller G, Mespouille L, Mottet D, Piel G. PEGylated and Functionalized Aliphatic Polycarbonate Polyplex Nanoparticles for Intravenous Administration of HDAC5 siRNA in Cancer Therapy. ACS Appl Mater Interfaces 2017;9:2181-95. [DOI: 10.1021/acsami.6b15064] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
59 Furue M, Kadono T. New aspects of the clinicopathological features and treatment of mycosis fungoides and Sézary syndrome. J Dermatol 2015;42:941-4. [PMID: 26432429 DOI: 10.1111/1346-8138.13083] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
60 Vaiserman AM, Lushchak OV, Koliada AK. Anti-aging pharmacology: Promises and pitfalls. Ageing Res Rev 2016;31:9-35. [PMID: 27524412 DOI: 10.1016/j.arr.2016.08.004] [Cited by in Crossref: 96] [Cited by in F6Publishing: 102] [Article Influence: 13.7] [Reference Citation Analysis]
61 Li Y, Seto E. HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med 2016;6:a026831. [PMID: 27599530 DOI: 10.1101/cshperspect.a026831] [Cited by in Crossref: 539] [Cited by in F6Publishing: 582] [Article Influence: 77.0] [Reference Citation Analysis]
62 Ganai SA, Banday S, Farooq Z, Altaf M. Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders. Pharmacology & Therapeutics 2016;166:106-22. [DOI: 10.1016/j.pharmthera.2016.07.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
63 Ropio J, Merlio JP, Soares P, Chevret E. Telomerase Activation in Hematological Malignancies. Genes (Basel) 2016;7:E61. [PMID: 27618103 DOI: 10.3390/genes7090061] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
64 Li C, Tao Y, Li C, Liu B, Liu J, Wang G, Liu H. PU.1-Bim axis is involved in Trichostatin A-induced apoptosis in murine pro-B lymphoma FL5.12 cells. Acta Biochim Biophys Sin (Shanghai) 2016;48:850-5. [PMID: 27451443 DOI: 10.1093/abbs/gmw067] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
65 Joosten M, Ginzel S, Blex C, Schmidt D, Gombert M, Chen C, Linka RM, Gräbner O, Hain A, Hirsch B, Sommerfeld A, Seegebarth A, Gruber U, Maneck C, Zhang L, Stenin K, Dieks H, Sefkow M, Münk C, Baldus CD, Thiele R, Borkhardt A, Hummel M, Köster H, Fischer U, Dreger M, Seitz V. A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B-cell lymphoma. Mol Oncol 2016;10:1232-44. [PMID: 27324824 DOI: 10.1016/j.molonc.2016.06.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
66 Newbold A, Falkenberg KJ, Prince HM, Johnstone RW. How do tumor cells respond to HDAC inhibition? FEBS J 2016;283:4032-46. [PMID: 27112360 DOI: 10.1111/febs.13746] [Cited by in Crossref: 77] [Cited by in F6Publishing: 83] [Article Influence: 11.0] [Reference Citation Analysis]
67 Ganai SA. Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies. J Chemother 2016;28:247-54. [PMID: 27121910 DOI: 10.1080/1120009X.2016.1145375] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
68 Leus NG, van der Wouden PE, van den Bosch T, Hooghiemstra WTR, Ourailidou ME, Kistemaker LE, Bischoff R, Gosens R, Haisma HJ, Dekker FJ. HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-κB p65 transcriptional activity. Biochem Pharmacol 2016;108:58-74. [PMID: 26993378 DOI: 10.1016/j.bcp.2016.03.010] [Cited by in Crossref: 71] [Cited by in F6Publishing: 75] [Article Influence: 10.1] [Reference Citation Analysis]
69 D'Urzo A, Boichenko AP, van den Bosch T, Hermans J, Dekker F, Andrisano V, Bischoff R. Site-specific quantification of lysine acetylation in the N-terminal tail of histone H4 using a double-labelling, targeted UHPLC MS/MS approach. Anal Bioanal Chem 2016;408:3547-53. [PMID: 26968571 DOI: 10.1007/s00216-016-9431-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
70 Ganai SA. Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance. Pharmaceutical Biology 2016;54:1926-35. [DOI: 10.3109/13880209.2015.1135966] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
71 van den Bosch T, Leus NG, Timmerman T, Dekker FJ. Small Molecule Inhibitors of Histone Deacetylases and Acetyltransferases as Potential Therapeutics in Oncology. Drug Discovery in Cancer Epigenetics 2016. [DOI: 10.1016/b978-0-12-802208-5.00008-4] [Reference Citation Analysis]
72 Ambasta RK, Kumar D, Sawhney P, Gupta R, Yadav P, Pabari P, Kumar P. Epigenesis in Colorectal Cancer: A Lethal Change in the Cell. Epigenetic Advancements in Cancer 2016. [DOI: 10.1007/978-3-319-24951-3_6] [Reference Citation Analysis]
73 van den Bosch T, Boichenko A, Leus NGJ, Ourailidou ME, Wapenaar H, Rotili D, Mai A, Imhof A, Bischoff R, Haisma HJ, Dekker FJ. The histone acetyltransferase p300 inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylases. Biochem Pharmacol 2016;102:130-40. [PMID: 26718586 DOI: 10.1016/j.bcp.2015.12.010] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
74 Ferreira AC, de-Freitas-Junior JC, Morgado-Díaz JA, Ridley AJ, Klumb CE. Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration. J Leukoc Biol 2016;99:569-78. [PMID: 26561567 DOI: 10.1189/jlb.2A0415-162R] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
75 Ganai SA. Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance. Arch Pharm Res . [DOI: 10.1007/s12272-015-0673-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
76 Markozashvili D, Ribrag V, Vassetzky YS. Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies. Invest New Drugs 2015;33:1280-91. [PMID: 26423245 DOI: 10.1007/s10637-015-0290-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
77 Szymanski W, Ourailidou ME, Velema WA, Dekker FJ, Feringa BL. Light-Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy. Chemistry 2015;21:16517-24. [PMID: 26418117 DOI: 10.1002/chem.201502809] [Cited by in Crossref: 97] [Cited by in F6Publishing: 99] [Article Influence: 12.1] [Reference Citation Analysis]